Insulin glargine U100 (Lantus) and U300 (Toujeo) contain the same active insulin glargine molecule but at different concentrations: 100 units/mL and 300 units/mL, respectively. This threefold concentration difference produces clinically meaningful pharmacokinetic and pharmacodynamic distinctions that influence hypoglycemia risk, dosing flexibility, and patient selection.
Molecular Identity
Section titled “Molecular Identity”Both formulations contain insulin glargine — a recombinant human insulin analogue with two amino acid substitutions (Gly₂₁ for Asn₂₁, and two Arg residues at the C-terminus of the B chain) and a glycine linker for A₂₁ Gly substitution. These modifications shift the isoelectric point to ~6.7, causing precipitation at physiological pH after subcutaneous injection.
The critical difference is concentration:
- U100: 100 units/mL (1.0 mL cartridge, 3 mL pen)
- U300: 300 units/mL (0.3 mL cartridge, 1.5 mL pen)
The higher concentration produces a smaller subcutaneous depot for the same unit dose, fundamentally altering the absorption profile.
Pharmacokinetic Differences
Section titled “Pharmacokinetic Differences”Absorption and Distribution
Section titled “Absorption and Distribution”| Parameter | Glargine U100 | Glargine U300 |
|---|---|---|
| Subcutaneous depot volume (60 U) | 0.60 mL | 0.20 mL |
| Time to peak (Tmax) | ~8–12 hours | ~12–16 hours |
| Duration of action | ~24 hours | ~36 hours |
| Bioavailability | ~50–60% | ~50–60% |
| Distribution | Broader | More compact |
The smaller depot volume of U300 creates a more compact precipitate with a smaller surface area exposed to subcutaneous tissue fluid. This reduces the dissolution rate, producing a flatter, more prolonged absorption profile — effectively creating a “beyond-24-hour” basal insulin.
Glucose-Lowering Effect
Section titled “Glucose-Lowering Effect”| Parameter | Glargine U100 | Glargine U300 |
|---|---|---|
| Onset of action | ~2–4 hours | ~6 hours |
| Peak effect | ~8–12 hours | ~12–16 hours |
| Duration | ~24 hours | ~36 hours |
| Variability (CV) | Lower | Higher |
| Steady-state accumulation | Minimal | Moderate |
U300 achieves a flatter, more plateau-like glucose-lowering profile with reduced peak-to-trough fluctuation. However, its longer duration creates accumulation over 2–3 days, requiring more conservative dose titration.
Clinical Trial Evidence
Section titled “Clinical Trial Evidence”ORIGIN Trial (U100)
Section titled “ORIGIN Trial (U100)”The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial enrolled 12,537 patients with early type 2 diabetes and cardiovascular risk factors:
- Primary endpoint: Composite of CV death, nonfatal MI, and nonfatal stroke — no significant difference vs. standard care.
- Hypoglycemia: 7.2% experienced severe hypoglycemia over 6.2 years — lower than expected for basal insulin.
- HbA1c: Maintained near 6.5% with glargine-based therapy.
EDITION Trials (U300)
Section titled “EDITION Trials (U300)”The EDITION program directly compared U300 to U100 in various populations:
EDITION 1 (basal-bolus, T2D):
- Similar HbA1c reduction with U300 and U100.
- Nocturnal confirmed hypoglycemia: U300 reduced by 25% (rate ratio 0.75).
- Less weight gain with U300.
EDITION 2 (basal insulin alone or with OADs, T2D):
- Similar HbA1c reduction.
- Nocturnal confirmed hypoglycemia: U300 reduced by 21% (rate ratio 0.79).
- Less weight gain with U300.
EDITION 3 (insulin-naïve, T2D):
- Similar HbA1c reduction.
- Nocturnal confirmed hypoglycemia: U300 reduced by 36% (rate ratio 0.64).
- Less weight gain with U300.
EDITION 4 (basal insulin, T1D):
- Similar HbA1c reduction.
- Nocturnal confirmed hypoglycemia: U300 reduced by 31% (rate ratio 0.69).
- Less weight gain with U300.
Non-Inferiority Meta-Analysis
Section titled “Non-Inferiority Meta-Analysis”Pooled EDITION analysis (N=3,483):
- U300 achieved non-inferior HbA1c reduction with significantly lower nocturnal hypoglycemia risk.
- Hypoglycemia benefit most pronounced during titration period and overnight.
- U300 associated with ~0.3 kg less weight gain.
Hypoglycemia Risk Profile
Section titled “Hypoglycemia Risk Profile”| Hypoglycemia Type | Glargine U100 | Glargine U300 | Risk Reduction |
|---|---|---|---|
| Nocturnal (confirmed) | Higher | Lower | 25–36% |
| Severe | Similar | Similar | No difference |
| Symptomatic | Similar | Lower | ~15–20% |
| During titration | Higher | Lower | Significant |
The hypoglycemia benefit of U300 is most evident during the dose titration period and overnight, when the flatter absorption profile reduces the risk of late-night nadir-related hypoglycemia.
Dosing and Administration
Section titled “Dosing and Administration”| Parameter | Glargine U100 | Glargine U300 |
|---|---|---|
| Starting dose (T2D) | 10 U once daily | 10 U once daily |
| Starting dose (T1D) | ~⅓ of total daily dose | ~⅓ of total daily dose |
| Titration increment | 1–2 U every 3–4 days | 1–2 U every 3–4 days |
| Maximum recommended | No fixed maximum | No fixed maximum |
| Injection volume (60 U) | 0.6 mL | 0.2 mL |
| Needle gauge | 29–32G | 32G (fixed) |
| Pen system | SoloStar, OptiClik | Toujeo Pen |
Dose Conversion
Section titled “Dose Conversion”When converting from U100 to U300:
- Initial conversion: 1 U of U100 ≈ 1 U of U300 (unit-for-unit).
- Titration adjustment: Due to reduced variability and lower hypoglycemia risk, some patients may tolerate slightly higher doses on U300.
- Post-conversion titration: More conservative titration recommended (every 3–4 days) due to accumulation kinetics.
Patient Selection
Section titled “Patient Selection”When to Prefer U300
Section titled “When to Prefer U300”- Nocturnal hypoglycemia: Patients with recurrent nocturnal hypoglycemia on U100.
- Hypoglycemia unawareness: Reduced hypoglycemia frequency may improve safety.
- Elderly patients: Lower hypoglycemia risk is particularly valuable in older adults.
- Insulin-naïve patients: Starting with U300 may improve early acceptance and reduce titration-related hypoglycemia.
- Patients preferring smaller volumes: U300’s compact cartridge (0.3 mL vs 1.0 mL) is preferred by injection-averse patients.
When to Prefer U100
Section titled “When to Prefer U100”- Cost considerations: U100 is generally less expensive and more widely covered.
- Flexible dosing: U100’s shorter duration (~24 hours) allows more dose adjustment flexibility.
- Basal-bolus regimens: More predictable when combined with rapid-acting bolus insulin.
- Biosimilar availability: Multiple U100 glargine biosimilars reduce cost.
Cost and Access
Section titled “Cost and Access”| Factor | Glargine U100 | Glargine U300 |
|---|---|---|
| List price (monthly) | ~$150–200 | ~$300–450 |
| Biosimilar available | Yes (multiple) | No (patent protected) |
| Insurance coverage | Broad | Variable |
| 340B pricing | Available | Available |
| Patient assistance | Available | Available |
The cost differential is substantial, with U300 typically costing 2–3× more than U100. Biosimilar competition has further reduced U100 prices, making U100 the preferred choice when cost is a primary concern.
Summary
Section titled “Summary”Insulin glargine U100 and U300 share the same active molecule but differ meaningfully in clinical profile due to concentration-dependent pharmacokinetics. U300’s smaller subcutaneous depot produces a flatter, more prolonged glucose-lowering effect with 25–36% lower nocturnal hypoglycemia risk, making it preferable for patients with hypoglycemia concerns, elderly patients, and those initiating basal insulin. U100 offers cost advantages, dosing flexibility, and biosimilar availability that maintain its role as a first-line basal insulin option. The choice between them should balance hypoglycemia risk, cost, patient preference, and clinical context.